Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. (1s,2s,3r,4r)-3-((1s)-1-acetamido-2-ethylbutyl)-4-((amino(imino)methyl)amino)-2-hydroxycyclopentanecarboxylic Acid Trihydrate
2. 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic Acid
3. Bcx 1812
4. Bcx-1812
5. Bcx1812
6. Peramivir Trihydrate
7. Rapivab
8. Rwj 270201
9. Rwj-270201
10. Rwj270201
1. 330600-85-6
2. Bcx-1812
3. 229614-55-5
4. Rapiacta
5. Rwj-270201
6. Rapivab
7. Peramivir Anhydrous
8. Chebi:85202
9. Bcx1812
10. Bcx 1812
11. Peramivir, (+/-)-
12. Rwj270201
13. (1s,2s,3s,4r)-3-[(1s)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic Acid
14. 229614-56-6
15. Rwj 270201
16. 9zs94hqo3b
17. Idl9q29886
18. (1s,2s,3r,4r)-3-((s)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic Acid
19. 330600-85-6 (free)
20. (1s,2s,3r,4r)-4-carbamimidamido-3-[(1s)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic Acid
21. 3-(1-acetylamino-2-ethyl-butyl)-4-guanidino-2-hydroxy-cyclopentanecarboxylic Acid
22. 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic Acid
23. Bcz
24. Cyclopentanecarboxylic Acid, 3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1s,2s,3r,4r)-
25. (+/-)-peramivir
26. Peramivir [usan:inn]
27. Unii-9zs94hqo3b
28. Peramiflu
29. Unii-idl9q29886
30. S-021812
31. Cyclopentanecarboxylic Acid, 3-((1s)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1s,2s,3r,4r)-
32. Peramivir [inn]
33. Peramivir [mi]
34. Schembl744373
35. Bdbm5024
36. Chembl139367
37. Schembl12795462
38. Dtxsid10904727
39. Bcpp000117
40. (1s,2r,3r,4r)-3-(1-acetamido-2-ethyl-butyl)-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic Acid
41. Zinc3981610
42. Bdbm50181441
43. Hy-17015a
44. Mfcd09837902
45. Akos016007760
46. Akos037652424
47. Peramivir (+/-)-form [mi]
48. Cs-0638
49. Db06614
50. Dt-0029
51. Ncgc00346433-06
52. Ncgc00346433-07
53. (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane
54. (1s,2s,3r,4r)-3-((s)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentane-1-carboxylic Acid
55. Ac-22715
56. Cyclopentanecarboxylic Acid, 3-((1r)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1r,2r,3s,4s)-rel-
57. P2892
58. W19713
59. Ab01566838_01
60. 600p856
61. A896277
62. Q412734
63. (-)-(1s,2s,3r,4r)-3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic Acid
64. (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxycyclopentanecarboxylic Acid
65. (1s,2s,3r,4r)-3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxycyclopentanecarboxylic Acid Trihydrate
66. (1s,2s,3r,4r)-3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic Acid
67. (1s,2s,3r,4r)-3-[(1s)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic Acid
68. (1s,2s,3r,4r)-3-[(1s)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic Acid
69. (1s,2s,3s,4r)-4-[(diaminomethylidene)amino]-3-[(1s)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic Acid
70. Cyclopentanecarboxylic Acid, 3-((1s)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1r,2r,3s,4s)-rel-
Molecular Weight | 328.41 g/mol |
---|---|
Molecular Formula | C15H28N4O4 |
XLogP3 | 0 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 7 |
Exact Mass | 328.21105539 g/mol |
Monoisotopic Mass | 328.21105539 g/mol |
Topological Polar Surface Area | 151 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 460 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.
FDA Label
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Treatment of influenza
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
J05AH03
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AH - Neuraminidase inhibitors
J05AH03 - Peramivir
Peramivir is an inhibitor of influenza neuraminidase, preventing new virus particles from leaving infected cells.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Peramivir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Peramivir, including repackagers and relabelers. The FDA regulates Peramivir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Peramivir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Peramivir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Peramivir supplier is an individual or a company that provides Peramivir active pharmaceutical ingredient (API) or Peramivir finished formulations upon request. The Peramivir suppliers may include Peramivir API manufacturers, exporters, distributors and traders.
click here to find a list of Peramivir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Peramivir DMF (Drug Master File) is a document detailing the whole manufacturing process of Peramivir active pharmaceutical ingredient (API) in detail. Different forms of Peramivir DMFs exist exist since differing nations have different regulations, such as Peramivir USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Peramivir DMF submitted to regulatory agencies in the US is known as a USDMF. Peramivir USDMF includes data on Peramivir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Peramivir USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Peramivir suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Peramivir Drug Master File in Korea (Peramivir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Peramivir. The MFDS reviews the Peramivir KDMF as part of the drug registration process and uses the information provided in the Peramivir KDMF to evaluate the safety and efficacy of the drug.
After submitting a Peramivir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Peramivir API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Peramivir suppliers with KDMF on PharmaCompass.
A Peramivir written confirmation (Peramivir WC) is an official document issued by a regulatory agency to a Peramivir manufacturer, verifying that the manufacturing facility of a Peramivir active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Peramivir APIs or Peramivir finished pharmaceutical products to another nation, regulatory agencies frequently require a Peramivir WC (written confirmation) as part of the regulatory process.
click here to find a list of Peramivir suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Peramivir as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Peramivir API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Peramivir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Peramivir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Peramivir NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Peramivir suppliers with NDC on PharmaCompass.
Peramivir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Peramivir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Peramivir GMP manufacturer or Peramivir GMP API supplier for your needs.
A Peramivir CoA (Certificate of Analysis) is a formal document that attests to Peramivir's compliance with Peramivir specifications and serves as a tool for batch-level quality control.
Peramivir CoA mostly includes findings from lab analyses of a specific batch. For each Peramivir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Peramivir may be tested according to a variety of international standards, such as European Pharmacopoeia (Peramivir EP), Peramivir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Peramivir USP).
LOOKING FOR A SUPPLIER?